Monte Rosa Therapeutics (GLUE)

• Market cap: $298M
• 1 day: -4.77%
• 5 days: 1.55%
• 1 month: -19.05%
• 3 months: 15.04%
• 6 months: -20.59%
• Year to date: -35.44%
• 1 year: -34.15%
• 5 years: -78.33%
• 10 years: -78.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Employees: 142

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,330% more call options, than puts

Call options by funds: $429K | Put options by funds: $30K

182% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 17

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

8% more funds holding

Funds holding: 105 [Q1] → 113 (+8) [Q2]

4.2% more ownership

Funds ownership: 96.77% [Q1] → 100.97% (+4.2%) [Q2]

1% more capital invested

Capital invested by funds: $276M [Q1] → $280M (+$3.91M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]